| Year |
Citation |
Score |
| 2024 |
Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, Biel N, Ricks TK, Fu W, Hamed S, Li F, Sun JJ, Fan J, Schuck R, Grimstein M, et al. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, -Mutated Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302112. PMID 38381994 DOI: 10.1200/JCO.23.02112 |
0.331 |
|
| 2010 |
Waldo GL, Ricks TK, Hicks SN, Cheever ML, Kawano T, Tsuboi K, Wang X, Montell C, Kozasa T, Sondek J, Harden TK. Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex. Science (New York, N.Y.). 330: 974-80. PMID 20966218 DOI: 10.1126/Science.1193438 |
0.491 |
|
| 2009 |
Ricks TK, Trejo J. Phosphorylation of protease-activated receptor-2 differentially regulates desensitization and internalization. The Journal of Biological Chemistry. 284: 34444-57. PMID 19815543 DOI: 10.1074/Jbc.M109.048942 |
0.547 |
|
| 2007 |
Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. Journal of Cell Science. 120: 921-8. PMID 17344429 DOI: 10.1242/Jcs.03409 |
0.61 |
|
| 2006 |
Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Research. 66: 307-14. PMID 16397244 DOI: 10.1158/0008-5472.Can-05-1735 |
0.44 |
|
| Show low-probability matches. |